Please login to the form below

Not currently logged in
Email:
Password:

J&J to bring subsidiaries under one name

Johnson & Johnson is to bring its autonomous pharmaceutical subsidiaries under the name Janssen Pharmaceuticals by the end of 2011, with further plans to link its consumer and prescription marketing

US-based pharmaceutical and healthcare company Johnson & Johnson (J&J) is to bring its autonomous pharmaceutical subsidiaries under the Janssen Pharmaceuticals brand by the end of 2011.

As reported by the Financial Times, vice-chair at J&J, Sheri McCoy, said the names of companies acquired by J&J will be dropped in favour of the single identity.

Subsidiaries affected include the recently Centocor and Cilag, as well as Tibotec, which announced yesterday it would be operating under the name Janssen Therapeutics. All Tibotec brand names and organisational structures will remain in place and unchanged.

As well as the brand changes, McCoy also announced plans for greater linking between marketing activities for its prescription and consumer products.

Pilot projects have been arranged to market over-the-counter and prescription products together according to McCoy, with therapy areas under consideration including skincare and baby products.

J&J's pharmaceuticals business generated $22.4bn in sales during 2010, representing 36 per cent of J&J's total revenue.

McCoy is a possible successor to lead J&J, with current chair William Weldon likely to step down next year following the relaunch of several products recalled over 2010.

28th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics